[F:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[O:9][C:10]3[CH:20]=[C:19]([N:21]([CH3:26])[S:22]([CH3:25])(=[O:24])=[O:23])[C:18](B4OC(C)(C)C(C)(C)O4)=[CH:17][C:11]=3[C:12]=2[C:13]([NH:15][CH3:16])=[O:14])=[CH:4][CH:3]=1.Br[C:37]1[CH:52]=[N:51][C:40]2[NH:41][CH:42]([C:46]3[S:47][CH:48]=[CH:49][CH:50]=3)[NH:43][C:44](=[O:45])[C:39]=2[CH:38]=1>O1CCOCC1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.Cl[Pd]Cl.[Fe+2]>[F:1][C:2]1[CH:3]=[CH:4][C:5]([C:8]2[O:9][C:10]3[CH:20]=[C:19]([N:21]([CH3:26])[S:22]([CH3:25])(=[O:23])=[O:24])[C:18]([C:37]4[CH:52]=[N:51][C:40]5[NH:41][CH:42]([C:46]6[S:47][CH:48]=[CH:49][CH:50]=6)[NH:43][C:44](=[O:45])[C:39]=5[CH:38]=4)=[CH:17][C:11]=3[C:12]=2[C:13]([NH:15][CH3:16])=[O:14])=[CH:6][CH:7]=1To a mixture of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzofuran-3-carboxamide (150 mg, 0.30 mmol), compound 6-bromo-2-(thiophen-2-yl)-2,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one (112 mg, 0.36 mmol) and K3PO4.3H2O (239 mg, 0.90 mmol) in 1,4-dioxane (3 mL), Pd(dppf)Cl2 (20 mg) was added under N2 protection. After being stirred at 80° C. overnight, the reaction mixture was concentrated in vacuo, suspended in water and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by prep-HPLC to give the product of 2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)-5-(4-oxo-2-(thiophen-2-yl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl)benzofuran-3-carboxamide (40 mg, yield: 22%). 1H-NMR (DMSO-d6, 400 MHz) δ 8.80 (d, J=1.6 Hz, 1H), 8.51 (d, J=4.4 Hz, 1H), 8.26 (d, J=2.0 Hz, 1H), 8.22 (s, 1H), 7.95˜8.05 (m, 4H), 7.60 (s, 1H), 7.47 (dd, J=5.2, 1.2 Hz, 1H), 7.41 (t, J=8.8 Hz, 2H), 7.12 (d, J=2.8 Hz, 1H), 7.00 (dd, J=4.8, 3.2 Hz, 1H), 6.14 (d, J=2.4 Hz, 1H), 3.14 (s, 3H), 2.98 (s, 3H), 2.83 (d, J=4.4 Hz, 3H). MS (M+H)+: 606